Overview

2 Week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Yrs) With Neurogenic Detrusor Overactivity

Status:
Terminated

Trial end date:
2013-05-23

Target enrollment:

Participant gender:

Summary

This study will evaluate the pharmacodynamics and pharmacokinetics of darifenacin liquid oral suspension in children, ages 2-15 years, with neurogenic detrusor overactivity. The results will support a benefit-risk based dosage recommendation for phase IIIa clinical trials.

Phase:

Phase 2

Details

Lead Sponsor:

Warner Chilcott

Treatments:

Darifenacin